Update on Tumor Neoantigens and Their Utility: Why It Is Good to Be Different  Chung-Han Lee, Roman Yelensky, Karin Jooss, Timothy A. Chan  Trends in Immunology  Volume 39, Issue 7, Pages 536-548 (July 2018) DOI: 10.1016/j.it.2018.04.005 Copyright © 2018 Elsevier Ltd Terms and Conditions

Figure 1 Tumor Mutational Load, Neoantigen Generation, and Therapeutic Efficacy. Tumor mutational load is shown in various tumor types. Likelihood of neoantigen generation is shown along the right axis. Green boxes show some tumor types that are associated with significant response rates with immune checkpoint blockade therapy. Tumors that are generated by genotoxins (UV, smoking) are noted. Adopted from [18]. Abbreviations: CAR, chimeric antigen receptor. Trends in Immunology 2018 39, 536-548DOI: (10.1016/j.it.2018.04.005) Copyright © 2018 Elsevier Ltd Terms and Conditions

Figure 2 Representative Tools and Workflow for Neoantigen Prediction. Diagram shows commonly used tools for neoantigen prediction. Tool name and references are listed in the table below the diagram. Abbreviations: TAP, transporter-associated with antigen processing; TCR, T cell receptor. See [49,53,54,61,93,94]. Trends in Immunology 2018 39, 536-548DOI: (10.1016/j.it.2018.04.005) Copyright © 2018 Elsevier Ltd Terms and Conditions

Figure 3 Cancer Vaccines, Checkpoint Blockade, and Immune Activation. Top panel shows the effects of combined vaccine and immune checkpoint blockade therapy on T cell activity. Bottom panel displays the critical locations and immune activities that need to be enhanced in order to elicit long-term antitumor immunity. Trends in Immunology 2018 39, 536-548DOI: (10.1016/j.it.2018.04.005) Copyright © 2018 Elsevier Ltd Terms and Conditions